Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 10/11/14  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Timothy J. Triche

Wrong Dr. Timothy J. Triche?

Director of the Center for Person...

Childrens Hospital Los Angeles
4650 Sunset Blvd. MS#75
Los Angeles, California 90027
United States

Company Description: The hospital's Craniofacial and Cleft Center is housed in the Division of Plastic and Maxillofacial Surgery. Children's Hospital Los Angeles has been named the...   more
Background

Employment History

Board Memberships and Affiliations

Education

  • MD
  • PhD
    Tulane University
  • BSc , Physics
    Cornell University
  • PhD
    Tulane Univeristy
  • MD PhD Chief Medical Officer
  • MD/PhD
    University of Southern California
158 Total References
Web References
Timothy J. Triche, ...
www.ltcreit.com, 11 Oct 2014 [cached]
Timothy J. Triche, MD
Dr. Triche has been the Director of the Center for Personalized Medicine at Children's Hospital Los Angeles since July 2010 and previously served as the Chairman of the Department of Pathology and Laboratory Medicine at Children's Hospital Los Angeles since 1988. He has also been a Professor of Pathology and Pediatrics at the University of Southern California Keck School of Medicine in Los Angeles, California since 1988. He also serves on the Board of Directors of Novelix Pharmaceuticals, Inc., a private California-based biotechnology company, NanoValent Pharmaceuticals, Inc., a private nanotechnology company, GenomeDx, a private Canadian biotechnology company developing prognostic tests for cancer, Silicon Valley Biosystems, a private California-based biotechnology company, and Sanguine BioSciences, a private biomedical research company.
Dr. Triche brings to the Board of LTC Properties, Inc. his experience as current and past executive and director experience with other health care companies, and his overall background in the health care industry.
To us, the word 'actionable means ...
www.svbio.com, 15 Jan 2013 [cached]
To us, the word 'actionable means finding a precise diagnosis for a case; reducing risk for family members; and predicting if treatments will be effective or futile," said Tim Triche, M.D., Ph.D., a clinician with 30 years of scientific and medical experience at pioneering companies including OncorMed, Genelogic, and GenomeDx and also Chairman of Pathology at Children's Hospital of Los Angeles, who serves on the company's Board of Directors.
...
"This is the new wave of genomics medicine; one that we expect to set new precedents and have a major impact on healthcare overall," said Dr. Triche. SV Bio is currently providing diagnostic testing services to physicians and centers of excellence for all heritable genetic conditions.
...
SV Bio's Board of Directors includes Timothy Triche, M.D., Ph.D., of the Center for Personalized Medicine, Children's Hospital Los Angeles; Warren Hogarth, Ph.D., M.B.A., a partner at Sequoia Capital; Todd Cozzens, M.B.A., formerly of Picis, who serves as SV Bio's Chairman; and Jeremy Friese, M.D., M.B.A., who leads business development for Mayo Clinic's Center for Individualized and practices medicine at Mayo Clinic.
Timothy Triche MD, ...
genomedx.com, 31 July 2014 [cached]
Timothy Triche MD, PhD Chairman and Chief Medical Officer
...
Timothy Triche Dr. Triche is a board-certified anatomical and molecular pathologist and academic professor of pathology and laboratory medicine. Tim has built, operated and owned high-complexity molecular diagnostics testing laboratories for the past 30 years and runs the GenomeDx clinical laboratory. Previously, he was the director of Specialized Diagnostics and Section Chief for the Laboratory of Pathology at the National Cancer Institute before becoming Pathologist-in-Chief at Children's Hospital of Los Angeles and Vice-Chair for the Department of Pathology at the Keck School of Medicine at the University of Southern California. Currently, Dr. Triche is the director of the Center for Personalized Medicine at Children's Hospital Los Angeles and co-director of the Ronald A. Matriarcia Institute for Molecular Medicine at Phoenix Children's Hospital. He is a founding member of the Association for Molecular Pathology and has previously served as a senior executive in a number of medical companies, including founder and CEO of Oncomed Inc., which pioneered the use of hereditary genetic testing in oncology. Dr. Triche received his BSc in Physics at Cornell University, MD and PhD at Tulane University and completed his residency in anatomical pathology at Washington University School of Medicine. Tim's research in the field of applied genomics and the molecular biology of cancer has been recognized by numerous awards, grants and over 200 peer-reviewed publications. His goal in co-founding GenomeDx was to realize the promise of genomic technology towards improving the practice of cancer medicine.
...
Dr. Davicioni trained as a pathobiologist in the genomics laboratory of Professor Triche before becoming an entrepreneur, raising over $20M in grant funding and equity financing to launch GenomeDx.
Dr. Timothy Triche | PROOF Centre
www.proofcentre.ca, 3 Mar 2011 [cached]
Dr. Timothy Triche
...
Dr. Timothy Triche
...
Dr. Timothy Triche is Chief of the Department of Pathology at Children's Hospital Los Angeles and newly appointed Director of the Center for Personalized Medicine at CHLA. He also serves as Vice Chair, Department of Pathology and Professor of Pathology and Pediatrics at the Keck School of Medicine of the University of Southern California. Prior to joining Children's Hospital, Dr. Triche was Head of Molecular Diagnostics at the National Cancer Institute. He is a Beckman Fellow of the Beckman Macular Research Center at the Doheny Eye Institute, and serves on the Board of Directors of LTC Properties Corporation, GenomeDx, Nanovalent, and Novellix. He is also a standing member of NCI Subcommittees C, D, and E, and serves as Associate Chair for Translational Research in Children's Oncology Group. Professional memberships include the American Medical Association; United States and Canadian Academy of Pathology/Society for Pediatric Pathology; American Association for Cancer Research, and Association of Molecular Pathology (where he was a founding member of the solid tumor division). He also served as CEO and founder of OncorMed, a cancer predisposition company that developed several cancer predisposition tests, notably BRCA1 and 2, and several others.
He has been continuously NIH grant funded since joining USC/CHLA, including as PI on sequential NCI Director's Challenge and SPECS awards totalling over $15 million, and has published over 200 articles in the peer reviewed literature. He has also established numerous collaborations with emerging biotechnology companies, has helped develop clinical applications for key technologies like microarrays, and is currently supporting biomedical application development of single-molecule 'next gen' DNA sequencing. Since 2004, Dr. Triche has been voted by his peers as one of the "Best Doctors in America.
Timothy J. Triche, ...
www.sec.gov, 28 April 2014 [cached]
Timothy J. Triche, MD Director since 2000
...
Dr. Triche has been the Director of the Center for Personalized Medicine at Children's Hospital Los Angeles since July 2010 and previously served as the Chairman of the Department of Pathology and Laboratory Medicine at Children's Hospital Los Angeles since 1988. He has also been a Professor of Pathology and Pediatrics at the University of Southern California Keck School of Medicine in Los Angeles, California since 1988. He also serves on the Board of Directors of Novelix Pharmaceuticals, Inc., a private California-based biotechnology company, NanoValent Pharmaceuticals, Inc., a private nanotechnology company, GenomeDx, a private Canadian biotechnology company developing prognostic tests for cancer, Silicon Valley Biosystems, a private California-based biotechnology company, and Sanguine BioSciences, a private biomedical research company.
Dr. Triche's prior service as an independent director of LTC Properties, Inc., current and past executive and director experience with other health care companies, and his overall background in the health care industry led the Board to conclude he should be nominated to serve another term as director.
Other People with the name "Triche":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304